CN114588307B - Alginate dressing and preparation method thereof - Google Patents
Alginate dressing and preparation method thereof Download PDFInfo
- Publication number
- CN114588307B CN114588307B CN202210362781.3A CN202210362781A CN114588307B CN 114588307 B CN114588307 B CN 114588307B CN 202210362781 A CN202210362781 A CN 202210362781A CN 114588307 B CN114588307 B CN 114588307B
- Authority
- CN
- China
- Prior art keywords
- alginate
- parts
- chitosan
- solution
- heating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an alginate dressing and a preparation method thereof, and relates to the technical field of medical dressings. The alginate dressing comprises the following raw materials in parts by weight: 10-30 parts of alginate, 10-30 parts of chitosan, 0.8-1.4 parts of sodium chloride, 5-15 parts of alginate ester, 0.3-0.8 part of polypeptide, 0.5-1.2 parts of collagen, 0.4-1.0 part of cellulose, 1.5-2.5 parts of oxalic acid, 0.4-1.0 part of glycosaminoglycan, 0.3-0.8 part of hydrogenated lecithin, 0.08-0.12 part of frankincense extract and 0.1-0.5 part of olive leaf extract. The alginate dressing prepared by the invention has the comprehensive effects of high hygroscopicity, bacteria resistance, strong adhesion, inflammation diminishing, hemostasis and pain relieving, can keep the wound surface in a moderate humid environment, and promotes the wound surface to heal quickly.
Description
Technical Field
The invention relates to the technical field of medical dressings, in particular to an alginate dressing and a preparation method thereof.
Background
The main component of the alginate dressing is alginate, and the alginate is natural polysaccharide carbohydrate extracted from seaweed and is natural cellulose. The alginate dressing is a functional wound dressing with high absorption performance, and after the dressing is contacted with wound exudate, a soft gel can be formed, so that an ideal moist environment is provided for wound healing, the wound healing is promoted, and the wound pain is relieved.
The existing alginate dressing generally has moisture absorption performance, but the existing alginate dressing has poor moisture absorption effect on wound exudate, is easy to cause infection of surrounding skin, has poor bacteriostatic effect and hemostatic and analgesic effect on a wound surface, and has longer healing time of the wound surface.
Disclosure of Invention
The invention aims to provide an alginate dressing which has high hygroscopicity, antibacterial property and hemostatic and analgesic effects.
The invention also aims to provide a preparation method of the alginate dressing, which has simple and convenient process and can prepare the alginate dressing with better comprehensive effect.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
On one hand, the embodiment of the application provides an alginate dressing which comprises the following raw materials in parts by weight: 10-30 parts of alginate, 10-30 parts of chitosan, 0.8-1.4 parts of sodium chloride, 5-15 parts of alginate ester, 0.3-0.8 part of polypeptide, 0.5-1.2 parts of collagen, 0.4-1.0 part of cellulose, 1.5-2.5 parts of oxalic acid, 0.4-1.0 part of glycosaminoglycan, 0.3-0.8 part of hydrogenated lecithin, 0.08-0.12 part of frankincense extract and 0.1-0.5 part of olive leaf extract.
In another aspect, an embodiment of the present application provides a method for preparing an alginate dressing, including the following steps:
performing modification treatment on chitosan, and dissolving the modified chitosan in oxalic acid solution to obtain modified chitosan solution;
adding alginate into the modified chitosan solution, mixing, adding sodium chloride, heating, adding alginate ester, and mixing to obtain wet spinning solution;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
adding deionized water into polypeptide, collagen, cellulose, glycosaminoglycan, hydrogenated lecithin, olibanum extract and folium Canarii albi extract, heating and mixing to obtain soaking solution;
soaking alginate fiber in the soaking solution, taking out, drying, and sterilizing to obtain the final product.
Compared with the prior art, the embodiment of the invention has at least the following advantages or beneficial effects:
the alginate, the chitosan, the sodium chloride, the alginate ester, the polypeptide, the collagen, the cellulose, the oxalic acid, the glycosaminoglycan, the hydrogenated lecithin, the frankincense extract and the olive leaf extract are used as raw materials, the alginate and the chitosan are main components of alginate dressing, the alginate has high hygroscopicity, the chitosan is used as a naturally existing alkaline polysaccharide, has better biocompatibility and degradability, and has the effects of resisting bacteria, diminishing inflammation, stopping bleeding and the like, the alginate is polyanionic electrolyte, the chitosan is polycationic substance, the charges of the two raw materials are different, the two raw materials cannot stably exist in the solution during blending, and a homogeneous phase system cannot be formed; the polypeptide can destroy the cell wall of the bacteria to achieve the antibacterial effect, the bacteria can not generate resistance action aiming at the action mode of the polypeptide, the antibacterial effect of the alginate dressing can be improved by the cooperation of the polypeptide and the chitosan, the drug resistance can be avoided, but the polypeptide can be quickly cracked and disappeared when the polypeptide touches human body fluid such as blood or tissue fluid, the original bactericidal effect is lost, the cellulose can protect the polypeptide and avoid the cracking and disappearance, and the polypeptide, the chitosan and the cellulose perform sterilization under the synergistic action, so that the antibacterial effect can be maintained for a long time; the hydrogenated lecithin can improve the moisture absorption performance of alginate fibers, can be used as a surfactant, is convenient for polypeptide to quickly permeate into wounds for sterilization, the collagen and the glycosaminoglycan are matched to ensure that the alginate dressing has stronger wet tissue adhesion and stronger mechanical property, the frankincense extract and the chitosan are matched to enhance the anti-inflammation and analgesia effects, and the olive leaf extract has the repair and protection effects. The raw materials are matched with each other, so that the alginate dressing has the comprehensive effects of high hygroscopicity, bacteria resistance, strong adhesion, inflammation diminishing, hemostasis and pain relieving, the wound surface can be kept in a proper humid environment, and the rapid healing of the wound surface is promoted.
In addition, the preparation method has simple and convenient flow, and the chitosan is modified, so that hydrophilic groups are grafted on chitosan active groups, the biological characteristics of the chitosan are maintained, meanwhile, the antibacterial property and the water solubility are further improved, the hygroscopicity and the antibacterial property of alginate fibers are improved, and the alginate fibers are soaked in a soaking solution, so that beneficial components in the soaking solution are permeated into the alginate fibers to prepare the alginate dressing with improved comprehensive effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The embodiment of the invention provides an alginate dressing which comprises the following raw materials in parts by weight: 10 to 30 portions of alginate, 10 to 30 portions of chitosan, 0.8 to 1.4 portions of sodium chloride, 5 to 15 portions of alginate ester, 0.3 to 0.8 portion of polypeptide, 0.5 to 1.2 portions of collagen, 0.4 to 1.0 portion of cellulose, 1.5 to 2.5 portions of oxalic acid, 0.4 to 1.0 portion of glycosaminoglycan, 0.3 to 0.8 portion of hydrogenated lecithin, 0.08 to 0.12 portion of frankincense extract and 0.1 to 0.5 portion of olive leaf extract.
In the above embodiment, alginate, chitosan, sodium chloride, alginate ester, polypeptide, collagen, cellulose, oxalic acid, glycosaminoglycan, hydrogenated lecithin, frankincense extract and olive leaf extract are used as raw materials, alginate and chitosan are main components of alginate dressing, alginate has high hygroscopicity, chitosan is used as a naturally occurring basic polysaccharide, has good biocompatibility and degradability, and has antibacterial, anti-inflammatory and hemostatic effects, alginate is polyanionic electrolyte, chitosan is polycationic substance, the two raw materials have different charges, and cannot stably exist in a solution during blending, and a homogeneous phase system cannot be formed, so the invention takes sodium chloride as a charge shielding agent, can eliminate the charge strength of polyanion, so as to obtain a blending solution with stable anion and cation, and alginate ester can improve the gelling ability and moisture absorption performance of alginate fibers; the polypeptide can destroy the cell wall of the bacteria to achieve the antibacterial effect, the bacteria can not generate resistance action aiming at the action mode of the polypeptide, the antibacterial effect of the alginate dressing can be improved by the cooperation of the polypeptide and the chitosan, the drug resistance can be avoided, but the polypeptide can be quickly cracked and disappeared when the polypeptide touches human body fluid such as blood or tissue fluid, the original bactericidal effect is lost, the cellulose can protect the polypeptide and avoid the cracking and disappearance, and the polypeptide, the chitosan and the cellulose perform sterilization under the synergistic action, so that the antibacterial effect can be maintained for a long time; the hydrogenated lecithin has strong hydrophilicity and moisture retention, has strong affinity to skin and mucous membrane, can improve the moisture absorption performance of alginate fibers, can be used as a surfactant, is convenient for polypeptide to quickly permeate into wounds for sterilization, and simultaneously enables the skin to better absorb nutrient components such as frankincense extract, olive leaf extract and the like in alginate dressing; the alginate dressing has stronger wet tissue adhesion force and stronger mechanical property by matching the collagen with the glycosaminoglycan, and can be firmly adhered to the wound surface of a wound when the wound has more leachate; the frankincense extract can promote increase of multinuclear leukocyte, phagocytose dead blood cells and cells, improve metabolism, and enhance anti-inflammatory effect in combination with chitosan, and has analgesic effect due to n-octyl acetate in the frankincense extract; the olive leaf extract contains oleuropein and hydroxytyrosol with high activity, and has repairing and protecting effects, and can maintain skin cell viability and promote wound healing. The raw materials are matched with each other, so that the alginate dressing has the comprehensive effects of high hygroscopicity, bacteria resistance, strong adhesion, inflammation diminishing, hemostasis and pain relieving, the wound surface can be kept in a proper humid environment, and the rapid healing of the wound surface is promoted.
In some embodiments of the present invention, the raw materials are used in the following amounts by weight: 20 parts of alginate, 20 parts of chitosan, 1.2 parts of sodium chloride, 10 parts of alginate ester, 0.5 part of polypeptide, 0.8 part of collagen, 0.7 part of cellulose, 2.0 parts of oxalic acid, 0.7 part of glycosaminoglycan, 0.5 part of hydrogenated lecithin, 0.1 part of frankincense extract and 0.3 part of olive leaf extract. The use amount of the raw materials is further limited, so that the raw materials can be better combined and matched with each other, and the alginate dressing with better performance is prepared.
In some embodiments of the present invention, the alginate is one or more of sodium alginate, potassium alginate, ammonium alginate and calcium alginate. It can form gel to stop bleeding.
The embodiment of the invention also provides a preparation method of the alginate dressing, which comprises the following steps:
performing modification treatment on chitosan, and dissolving the modified chitosan in oxalic acid solution to obtain modified chitosan solution; adding alginate into the modified chitosan solution, mixing, adding sodium chloride, heating, adding alginate ester, and mixing to obtain wet spinning stock solution; preparing alginate fibers from the wet spinning stock solution through a wet spinning process; adding deionized water into polypeptide, collagen, cellulose, glycosaminoglycan, hydrogenated lecithin, olibanum extract and folium Canarii albi extract, heating and mixing to obtain soaking solution; soaking alginate fiber in the soaking solution, taking out, drying, and sterilizing to obtain the final product.
In the embodiment, the preparation method is simple and convenient in process, the chitosan is modified, the hygroscopicity and the antibacterial property of the alginate fibers are improved, and the alginate fibers are soaked in the soaking solution, so that the beneficial components in the soaking solution are permeated into the alginate fibers, and the alginate dressing with improved comprehensive effect is prepared.
In some embodiments of the present invention, the chitosan modification treatment specifically comprises the following steps: dissolving chitosan in 1-3% acetic acid solution by mass, magnetically stirring and dropwise adding 1-3% sodium hydroxide solution by mass, adjusting pH to 8-9, recovering chitosan to be solid under an alkaline environment, pouring out liquid, retaining solid, adding isopropanol, heating in an oil bath, stirring and heating to 78-83 ℃, adding epoxypropane trimethyl ammonium chloride aqueous solution, reacting for 7-9h at constant temperature, stopping heating, continuously stirring for 25-35min, taking out a product, performing suction filtration, washing with isopropanol for multiple times, and performing vacuum drying to obtain the modified chitosan. The chitosan is subjected to alkalization modification treatment, and hydrophilic groups are connected to chitosan active groups, so that the biological characteristics of the chitosan are maintained, and meanwhile, the antibacterial property and the water solubility are further improved.
In some embodiments of the present invention, the oxalic acid solution is 1-2% by weight. Chitosan is soluble in acidic solutions and precipitates solids in alkaline environments.
In some embodiments of the present invention, the heating condition in the step of preparing the wet spinning dope is heating in a water bath at 40-60 ℃ for 2-3 hours.
In some embodiments of the present invention, the heating condition in the step of preparing the soak solution is heating in a water bath at 35-45 ℃ for 1-2 hours.
In some embodiments of the invention, the soaking temperature is 25-35 ℃ and the soaking time is 10-12h. The temperature and time during soaking are limited, so that the beneficial components in the soaking solution can be fully infiltrated into the alginate fibers, and the alginate dressing with improved comprehensive effect can be prepared.
In some embodiments of the invention, vacuum freeze-drying is used for drying. By the freeze-drying technology, the original properties of the alginate dressing can be immediately recovered when the alginate dressing is contacted with the wound leachate, and the easily oxidized components can be prevented from being oxidized in the drying process.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
An alginate dressing prepared by the steps of:
performing modification treatment on 20g of chitosan, dissolving the chitosan in 1% by mass of acetic acid solution, performing magnetic stirring, dropwise adding 1% by mass of sodium hydroxide solution, adjusting the pH to 8, pouring out liquid, retaining solid, adding isopropanol, performing oil bath heating, stirring, heating to 80 ℃, adding an epoxypropane trimethyl ammonium chloride aqueous solution, reacting at constant temperature for 8 hours, stopping heating, continuing stirring for 30min, taking out a product, performing suction filtration, washing with isopropanol for multiple times, and performing vacuum drying to obtain modified chitosan;
dissolving 2.0g of oxalic acid in water to prepare an oxalic acid solution with the mass fraction of 1%, and dissolving modified chitosan in the oxalic acid solution to obtain a modified chitosan solution;
adding 20g of alginate into the modified chitosan solution, uniformly mixing, adding 1.2g of sodium chloride, heating in a water bath at 50 ℃ for 2.5h, adding 10g of alginate ester, and uniformly mixing to obtain a wet spinning stock solution, wherein the alginate is sodium alginate;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
taking 0.5g of polypeptide, 0.8g of collagen, 0.7g of cellulose, 0.7g of glycosaminoglycan, 0.5g of hydrogenated lecithin, 0.1g of frankincense extract and 0.3g of olive leaf extract, adding 1000g of deionized water, heating in water bath at 40 ℃ for 1.5h, and uniformly stirring to obtain a soaking solution;
soaking alginate fiber in the soaking solution at 30 deg.C for 11 hr, taking out, vacuum freeze drying, and sterilizing to obtain the final product.
Example 2
An alginate dressing prepared by the steps of:
modifying 10g of chitosan, dissolving the chitosan in 1% by mass of acetic acid solution, magnetically stirring and dropwise adding 1% by mass of sodium hydroxide solution, adjusting the pH to 8, pouring out liquid, keeping solid, adding isopropanol, heating in an oil bath, stirring and heating to 78 ℃, adding an epoxypropane trimethyl ammonium chloride aqueous solution, reacting at constant temperature for 7 hours, stopping heating, continuing stirring for 25min, taking out a product, performing suction filtration, washing with isopropanol for multiple times, and performing vacuum drying to obtain modified chitosan;
dissolving 1.5g of oxalic acid in water to prepare 1% oxalic acid solution, and dissolving modified chitosan in the oxalic acid solution to obtain a modified chitosan solution;
adding 10g of alginate into the modified chitosan solution, uniformly mixing, adding 0.8g of sodium chloride, heating in water bath at 40 ℃ for 2.0h, adding 5g of alginate ester, and uniformly mixing to obtain a wet spinning stock solution, wherein the alginate is potassium alginate;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
taking 0.3g of polypeptide, 0.5g of collagen, 0.4g of cellulose, 0.4g of glycosaminoglycan, 0.3g of hydrogenated lecithin, 0.08g of frankincense extract and 0.1g of olive leaf extract, adding 1000g of deionized water, heating in water bath at 35 ℃ for 1.0h, and uniformly stirring to obtain a soaking solution;
soaking alginate fiber in the soaking solution at 25 deg.C for 12 hr, taking out, vacuum freeze drying, and sterilizing to obtain the final product.
Example 3
An alginate dressing prepared by the steps of:
modifying 30g of chitosan, dissolving chitosan in 3% by mass of acetic acid solution, stirring by magnetic force, dropwise adding 3% by mass of sodium hydroxide solution, adjusting the pH to 9, pouring out liquid, retaining solid, adding isopropanol, heating in an oil bath, stirring and heating to 83 ℃, adding an epoxypropane trimethyl ammonium chloride aqueous solution, reacting at constant temperature for 9h, stopping heating, continuing stirring for 35min, taking out a product, carrying out suction filtration, washing with isopropanol for multiple times, and carrying out vacuum drying to obtain modified chitosan;
dissolving 2.0g of oxalic acid in water to prepare an oxalic acid solution with the mass fraction of 2%, and dissolving modified chitosan in the oxalic acid solution to obtain a modified chitosan solution;
adding 30g of alginate into the modified chitosan solution, uniformly mixing, adding 1.4g of sodium chloride, heating in a water bath at 60 ℃ for 3.0h, adding 15g of alginate ester, and uniformly mixing to obtain a wet spinning stock solution, wherein the alginate is the mixture of ammonium alginate and calcium alginate;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
taking 0.8g of polypeptide, 1.2g of collagen, 1.0g of cellulose, 1.0g of glycosaminoglycan, 0.8g of hydrogenated lecithin, 0.12g of frankincense extract and 0.5g of olive leaf extract, adding 1000g of deionized water, heating in water bath at 45 ℃ for 2.0h, and uniformly stirring to obtain a soaking solution;
soaking alginate fiber in the soaking solution at 35 deg.C for 10 hr, taking out, vacuum freeze drying, and sterilizing to obtain the final product.
Example 4
An alginate dressing prepared by the steps of:
performing modification treatment on 25g of chitosan, dissolving the chitosan in 2.5% acetic acid solution by mass, performing magnetic stirring, dropwise adding 2% sodium hydroxide solution by mass, adjusting the pH to 8.5, pouring out liquid, retaining solid, adding isopropanol, performing oil bath heating, stirring, heating to 81 ℃, adding an epoxypropane trimethyl ammonium chloride aqueous solution, reacting at constant temperature for 7.5h, stopping heating, continuously stirring for 28min, taking out a product, performing suction filtration, washing with isopropanol for multiple times, and performing vacuum drying to obtain modified chitosan;
dissolving 2.5g of oxalic acid in water to prepare oxalic acid solution with the mass fraction of 2%, and dissolving the modified chitosan in the oxalic acid solution to obtain modified chitosan solution;
adding 25g of alginate into the modified chitosan solution, uniformly mixing, adding 1.2g of sodium chloride, heating in a water bath at 45 ℃ for 2.4 hours, adding 12g of alginate, and uniformly mixing to obtain a wet spinning stock solution, wherein the alginate is calcium alginate;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
taking 0.4g of polypeptide, 0.9g of collagen, 0.8g of cellulose, 0.6g of glycosaminoglycan, 0.4g of hydrogenated lecithin, 0.09g of frankincense extract and 0.2g of olive leaf extract, adding 1000g of deionized water, heating in a water bath at 42 ℃ for 1.8h, and uniformly stirring to obtain a soaking solution;
soaking alginate fiber in the soaking solution at 28 deg.C for 11 hr, taking out, vacuum freeze drying, and sterilizing to obtain the final product.
Example 5
An alginate dressing prepared by the steps of:
modifying 18g of chitosan, dissolving the chitosan in 1.5% acetic acid solution by mass, magnetically stirring and dropwise adding 2.5% sodium hydroxide solution by mass, adjusting the pH to 9, pouring out liquid, retaining solid, adding isopropanol, heating in an oil bath, stirring and heating to 80 ℃, adding epoxypropane trimethyl ammonium chloride aqueous solution, reacting for 8.5h at constant temperature, stopping heating, continuously stirring for 30min, taking out a product, performing suction filtration, washing with isopropanol for multiple times, and performing vacuum drying to obtain modified chitosan;
dissolving 1.8g of oxalic acid in water to prepare 1% oxalic acid solution, and dissolving modified chitosan in the oxalic acid solution to obtain a modified chitosan solution;
adding 28g of alginate into the modified chitosan solution, uniformly mixing, adding 0.9g of sodium chloride, heating in a water bath at 55 ℃ for 2.7 hours, adding 7g of alginate ester, and uniformly mixing to obtain a wet spinning stock solution, wherein the alginate is the mixture of sodium alginate, potassium alginate and ammonium alginate;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
taking 0.5g of polypeptide, 0.7g of collagen, 0.6g of cellulose, 0.5g of glycosaminoglycan, 0.5g of hydrogenated lecithin, 0.09g of frankincense extract and 0.3g of olive leaf extract, adding 1000g of deionized water, heating in water bath at 38 ℃ for 1.8h, and uniformly stirring to obtain a soaking solution;
soaking alginate fiber in the soaking solution at 32 deg.C for 10.5 hr, taking out, vacuum freeze drying, and sterilizing to obtain the final product.
Comparative example 1
Comparative example 1 compared to example 1, no polypeptide was added to the starting material.
Comparative example 2
Comparative example 2 in comparison with example 1, no hydrogenated lecithin was added to the starting material.
Comparative example 3
Comparative example 3 compared to example 1, no modification treatment was performed on chitosan.
Examples of the experiments
1. Detection of imbibition Performance
The alginate dressings prepared in examples 1 to 3 and comparative examples 1 to 3 were selected, cut into 1.0cm × 1.0cm samples, and the dry weight Wg of each group of samples was measured, and then the samples were placed in physiological saline 40 times the mass of the samples and left at 37 ℃ for 0.5 hour, after which the samples were gripped and suspended in the air for 30 seconds, and the mass W1g was measured.
Liquid absorption amount of alginate dressing = (W1-W)/W, unit g -1 。
The test results are shown in table 1 below.
TABLE 1
| Group of | W(g) | W1(g) | Liquid absorption amount (g. G) -1 ) |
| Example 1 | 0.104 | 2.368 | 21.77 |
| Example 2 | 0.121 | 2.224 | 17.38 |
| Example 3 | 0.101 | 1.973 | 18.53 |
| Comparative example 1 | 0.112 | 1.997 | 16.83 |
| Comparative example 2 | 0.122 | 1.739 | 13.25 |
| Comparative example 3 | 0.128 | 1.633 | 11.76 |
As can be seen from Table 1, the alginate dressing prepared by the examples of the invention has excellent liquid absorption performance, the liquid absorption amount of the alginate dressing prepared by the examples of the invention is not greatly different from that of the examples without adding the polypeptide in comparative example 1, which shows that the influence of the addition of the polypeptide on the liquid absorption performance of the alginate dressing is not large, while the hydrogenated lecithin in comparative example 2 is not added, which has stronger hydrophilicity and moisture retention and has stronger affinity to skin and mucous membrane, so the liquid absorption performance of the comparative example 2 is greatly influenced, the chitosan in comparative example 3 is not modified, and the moisture absorption of the alginate can be increased after the modification of the chitosan, so the liquid absorption amount of the comparative example 3 is lower, and the experiment shows that the liquid absorption performance of the alginate dressing can be improved by adding the hydrogenated lecithin and modifying the chitosan in the formula.
2. Detection of antibacterial Properties
Alginate dressings prepared according to examples 1, 4, 5 and comparative examples 1-3 were selected and tested according to the YY/T0471.5 contact wound dressing test method, part 5, protocol for resistance to bacterial penetration under moist conditions, to evaluate the ability of wound alginate dressings to prevent bacterial penetration under moist conditions. The test results are shown in table 2 below.
TABLE 2
As can be seen from Table 2, the antibacterial rates of the alginate dressing prepared by the embodiment of the invention on staphylococcus aureus, escherichia coli and candida albicans are all more than 95%, the antibacterial rate is the lowest due to no polypeptide in the comparative example 1, the polypeptide can effectively kill various bacteria, the influence on the antibacterial performance is small due to no addition of hydrogenated lecithin in the comparative example 2, the chitosan is not modified in the comparative example 3, and the modified chitosan has a certain antibacterial effect, so the antibacterial rate in the comparative example 3 is low, and the experiment shows that the antibacterial performance of the alginate dressing can be improved due to addition of the hydrogenated lecithin and modification of the chitosan in the formula.
In conclusion, the invention provides an alginate dressing, which adopts alginate, chitosan, sodium chloride, alginate ester, polypeptide, collagen, cellulose, oxalic acid, glycosaminoglycan, hydrogenated lecithin, frankincense extract and olive leaf extract as raw materials, the alginate and the chitosan are main components of the alginate dressing, the alginate has high hygroscopicity, the chitosan is used as a naturally-existing alkaline polysaccharide, has better biocompatibility and degradability, and has the effects of antibiosis, antiphlogosis, hemostasis and the like, the alginate is polyanion electrolyte, the chitosan is polycation substance, the charges of the two raw materials are different, the two raw materials cannot stably exist in a solution during blending, and a homogeneous phase system cannot be formed, so the sodium chloride is used as a charge shielding agent, the charge intensity of the polyion and the zwitterion can be eliminated, so as to obtain a stable blending solution, and meanwhile, the alginate ester can improve the gelling ability and the moisture absorption performance of alginate fibers; the polypeptide can destroy the cell wall of the bacteria to achieve the antibacterial effect, the bacteria can not generate resistance action aiming at the action mode of the polypeptide, the antibacterial effect of the alginate dressing can be improved by the cooperation of the polypeptide and the chitosan, the drug resistance can be avoided, but the polypeptide can be quickly cracked and disappeared when the polypeptide touches human body fluid such as blood or tissue fluid, the original bactericidal effect is lost, the cellulose can protect the polypeptide and avoid the cracking and disappearance, and the polypeptide, the chitosan and the cellulose perform sterilization under the synergistic action, so that the antibacterial effect can be maintained for a long time; the hydrogenated lecithin has strong hydrophilicity and moisture retention, has strong affinity to skin and mucous membrane, can improve the moisture absorption performance of alginate fibers, can be used as a surfactant, is convenient for polypeptide to quickly permeate into wounds for sterilization, and simultaneously enables the skin to better absorb nutrient components such as frankincense extract, olive leaf extract and the like in the alginate dressing; the alginate dressing has stronger wet tissue adhesion force and stronger mechanical property by matching the collagen with the glycosaminoglycan, and can be firmly adhered to the wound surface of a wound when the wound has more leachate; the frankincense extract can promote increase of multinuclear leukocyte, phagocytose dead blood cells and cells, improve metabolism, and enhance anti-inflammatory effect in combination with chitosan, and has analgesic effect due to n-octyl acetate in the frankincense extract; the olive leaf extract contains oleuropein and hydroxytyrosol with high activity, and has repairing and protecting effects, and can maintain skin cell viability and promote wound healing. The raw materials are matched with each other, so that the alginate dressing has the comprehensive effects of high hygroscopicity, bacteria resistance, strong adhesion, inflammation diminishing, hemostasis and pain relieving, the wound surface can be kept in a proper humid environment, and the rapid healing of the wound surface is promoted.
In addition, the invention also provides a preparation method of the alginate dressing, the preparation method has simple and convenient flow, and the chitosan is modified, so that the hydrophilic group is connected to the chitosan active group, the biological characteristics of the chitosan are maintained, meanwhile, the antibacterial property and the water solubility are further improved, the hygroscopicity and the antibacterial property of the alginate fibers are improved, the alginate fibers are soaked in the soaking solution, and the beneficial components in the soaking solution are infiltrated into the alginate fibers to prepare the alginate dressing with improved comprehensive effect.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The alginate dressing is characterized by comprising the following raw materials in parts by weight: 10-30 parts of alginate, 10-30 parts of chitosan, 0.8-1.4 parts of sodium chloride, 5-15 parts of alginate ester, 0.3-0.8 part of polypeptide, 0.5-1.2 parts of collagen, 0.4-1.0 part of cellulose, 1.5-2.5 parts of oxalic acid, 0.4-1.0 part of glycosaminoglycan, 0.3-0.8 part of hydrogenated lecithin, 0.08-0.12 part of frankincense extract and 0.1-0.5 part of olive leaf extract.
2. The alginate dressing according to claim 1, wherein the raw materials are used in the following amounts, respectively, in parts by weight: 20 parts of alginate, 20 parts of chitosan, 1.2 parts of sodium chloride, 10 parts of alginate ester, 0.5 part of polypeptide, 0.8 part of collagen, 0.7 part of cellulose, 2.0 parts of oxalic acid, 0.7 part of glycosaminoglycan, 0.5 part of hydrogenated lecithin, 0.1 part of frankincense extract and 0.3 part of olive leaf extract.
3. The alginate dressing of claim 1 or 2 wherein the alginate is a mixture of one or more of sodium alginate, potassium alginate, ammonium alginate and calcium alginate.
4. A method of making an alginate dressing according to any one of claims 1 to 3 comprising the steps of:
performing modification treatment on chitosan, and dissolving the modified chitosan in oxalic acid solution to obtain modified chitosan solution;
adding alginate into the modified chitosan solution, mixing uniformly, adding sodium chloride, heating, adding alginate ester, and mixing uniformly to obtain wet spinning stock solution;
preparing alginate fibers from the wet spinning stock solution through a wet spinning process;
adding deionized water into polypeptide, collagen, cellulose, glycosaminoglycan, hydrogenated lecithin, olibanum extract and folium Canarii albi extract, heating and mixing to obtain soaking solution;
soaking alginate fiber in the soaking solution, taking out, drying, and sterilizing to obtain the final product.
5. The method for preparing the alginate dressing according to claim 4, wherein the specific steps of the chitosan modification treatment are as follows: dissolving chitosan in 1-3% acetic acid solution by mass, stirring by magnetic force, dropwise adding 1-3% sodium hydroxide solution by mass, adjusting pH to 8-9, pouring out liquid, reserving solid, adding isopropanol, heating by oil bath, stirring, heating to 78-83 ℃, adding epoxypropane trimethyl ammonium chloride aqueous solution, reacting at constant temperature for 7-9h, stopping heating, continuing stirring for 25-35min, taking out a product, performing suction filtration, washing with isopropanol for multiple times, and performing vacuum drying to obtain the modified chitosan.
6. The method for preparing an alginate dressing according to claim 4 wherein the mass fraction of the oxalic acid solution is 1-2%.
7. The method for preparing an alginate dressing according to claim 4, wherein the heating condition in the step of preparing the wet spinning dope is heating in a water bath at 40-60 ℃ for 2-3h.
8. The method for preparing an alginate dressing according to claim 4, wherein the heating condition in the step of preparing the soaking solution is heating in a water bath at 35-45 ℃ for 1-2h.
9. The method for preparing the alginate dressing according to claim 4, wherein the soaking temperature is 25-35 ℃ and the soaking time is 10-12h.
10. The method for preparing an alginate dressing according to claim 4 wherein vacuum freeze drying is used for drying.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210362781.3A CN114588307B (en) | 2022-04-08 | 2022-04-08 | Alginate dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210362781.3A CN114588307B (en) | 2022-04-08 | 2022-04-08 | Alginate dressing and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114588307A CN114588307A (en) | 2022-06-07 |
| CN114588307B true CN114588307B (en) | 2022-12-23 |
Family
ID=81813127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210362781.3A Active CN114588307B (en) | 2022-04-08 | 2022-04-08 | Alginate dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114588307B (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5836970A (en) * | 1996-08-02 | 1998-11-17 | The Kendall Company | Hemostatic wound dressing |
| CN101343334A (en) * | 2008-07-16 | 2009-01-14 | 深圳大学 | The preparation method of O-2'-hydroxypropyltrimethylammonium chloride chitosan |
| CN102031590A (en) * | 2011-01-12 | 2011-04-27 | 武汉理工大学 | Novel method for preparing sodium alginate/hydroxypropyl chitosan antibacterial blended fiber |
| CN102552966A (en) * | 2012-01-31 | 2012-07-11 | 青岛明药堂医药科技开发有限公司 | Alginate antibacterial dressing and its preparation method |
| CN102822413A (en) * | 2010-03-24 | 2012-12-12 | 利普泰股份公司 | Process of treatment of fibers and/or textile materials |
| CN105683426A (en) * | 2013-09-13 | 2016-06-15 | 艾克希罗斯有限公司 | Method of producing a swellable polymer fibre |
| CN106894111A (en) * | 2017-03-30 | 2017-06-27 | 广东泰宝医疗科技股份有限公司 | A kind of preparation method of the compound alginate dressing of soft moisture absorption |
| CN107029272A (en) * | 2017-04-10 | 2017-08-11 | 河南汇博医疗股份有限公司 | A kind of alginate medical dressing and preparation method thereof |
| CN107237005A (en) * | 2017-06-19 | 2017-10-10 | 山东大学 | A kind of alginic acid and chitosan bicomponent fibers and preparation method thereof |
| CN108714239A (en) * | 2018-05-30 | 2018-10-30 | 广东泰宝医疗器械技术研究院有限公司 | A kind of high liquid-absorbing chitosan anti-bacteria glue dressing and preparation method thereof |
| CN112410931A (en) * | 2020-12-03 | 2021-02-26 | 大连工业大学 | Sodium alginate/chitosan composite fiber and preparation method and application thereof |
-
2022
- 2022-04-08 CN CN202210362781.3A patent/CN114588307B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5836970A (en) * | 1996-08-02 | 1998-11-17 | The Kendall Company | Hemostatic wound dressing |
| CN101343334A (en) * | 2008-07-16 | 2009-01-14 | 深圳大学 | The preparation method of O-2'-hydroxypropyltrimethylammonium chloride chitosan |
| CN102822413A (en) * | 2010-03-24 | 2012-12-12 | 利普泰股份公司 | Process of treatment of fibers and/or textile materials |
| CN102031590A (en) * | 2011-01-12 | 2011-04-27 | 武汉理工大学 | Novel method for preparing sodium alginate/hydroxypropyl chitosan antibacterial blended fiber |
| CN102552966A (en) * | 2012-01-31 | 2012-07-11 | 青岛明药堂医药科技开发有限公司 | Alginate antibacterial dressing and its preparation method |
| CN105683426A (en) * | 2013-09-13 | 2016-06-15 | 艾克希罗斯有限公司 | Method of producing a swellable polymer fibre |
| CN106894111A (en) * | 2017-03-30 | 2017-06-27 | 广东泰宝医疗科技股份有限公司 | A kind of preparation method of the compound alginate dressing of soft moisture absorption |
| CN107029272A (en) * | 2017-04-10 | 2017-08-11 | 河南汇博医疗股份有限公司 | A kind of alginate medical dressing and preparation method thereof |
| CN107237005A (en) * | 2017-06-19 | 2017-10-10 | 山东大学 | A kind of alginic acid and chitosan bicomponent fibers and preparation method thereof |
| CN108714239A (en) * | 2018-05-30 | 2018-10-30 | 广东泰宝医疗器械技术研究院有限公司 | A kind of high liquid-absorbing chitosan anti-bacteria glue dressing and preparation method thereof |
| CN112410931A (en) * | 2020-12-03 | 2021-02-26 | 大连工业大学 | Sodium alginate/chitosan composite fiber and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114588307A (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110522945B (en) | Medical biogel hemostatic dressing and preparation method thereof | |
| CN105641733A (en) | Preparation method for compound antibacterial haemostatic wound dressing | |
| DK161980B (en) | PH VALUE REGULATORY MATERIALS AND PROCEDURES FOR PRODUCING THEREOF | |
| CN114014953B (en) | Functionalized chitosan microsphere and preparation method and application thereof | |
| CN102031590A (en) | Novel method for preparing sodium alginate/hydroxypropyl chitosan antibacterial blended fiber | |
| CN107233612B (en) | Irradiation crosslinking hemostatic gel material and preparation method thereof | |
| CN104436279A (en) | Preparation method for medical biological antiseptic chitosan dressing | |
| CN107184961A (en) | A kind of competent cell renovation agent and preparation method thereof | |
| CN110507842B (en) | Bacterial cellulose/hyaluronic acid/epsilon-polylysine functional dressing and preparation method thereof | |
| CN109453411B (en) | Chitosan dressing | |
| CN107412843B (en) | Starch-based microporous hemostatic material with antibacterial property and preparation method and application thereof | |
| CN106344954A (en) | Bio-antimicrobial bacterial cellulose dressing and preparation method thereof | |
| CN113144281A (en) | Wound surface disinfection gel and preparation method thereof | |
| KR102088475B1 (en) | Manufacturing Method of HR-Chitosan Dressing and HR-Chitosan Dressing Thereby | |
| CN111228296A (en) | Cross-linked hyaluronic acid ectoine isotonic wound flushing fluid | |
| CN106492259A (en) | A kind of antibacterial soluble hemostatic material and preparation method thereof | |
| CN114588307B (en) | Alginate dressing and preparation method thereof | |
| CN103174017B (en) | Sodium alginate oxide modified chitosan fiber and preparation method and application thereof | |
| CN111450304A (en) | Positively charged biological fiber hemostatic and bacteriostatic material and preparation method and application thereof | |
| CN107261189B (en) | Preparation method of sisal fiber environment-friendly medical gauze | |
| CN107115554A (en) | A kind of efficient hemostasis is dispelled the compound dressing and preparation method thereof of pain | |
| CN113855849A (en) | Dressing composition and preparation method and application thereof | |
| CN111118878A (en) | Silver ion alginate wound dressing and preparation method thereof | |
| CN109432491B (en) | Slow-release hemostatic gauze | |
| CN115770323A (en) | Recombinant collagen gel dressing and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |